United States· US:71921-250_f742254f-781e-4e7a-ae0b-e79b8482980d
Lofexidine
A lofexidine product containing lofexidine hydrochloride, registered in United States by Florida Pharmaceutical Products, LLC. The same ATC class is registered in 2 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Lofexidine is registered in 2 of 19 countries.
Countries holding a registration under ATC N07BC04 (lofexidine), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 1 of them publish a price we can compare per daily dose
Lofexidine · ATC N07BC04
2 / 19 countries
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LOFEXIDINE HYDROCHLORIDE
- Manufacturer
- Florida Pharmaceutical Products, LLC
- Country
- United States (US)
- ATC code
- N07BC04
- ATC class
- Lofexidine
- Defined daily dose
- 1.4 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc1171921-250-36
- ndc1171921-250-96
- ndc1171921250361 BOTTLE in 1 CARTON (71921-250-36) / 36 TABLET, COATED in 1 BOTTLE
- ndc1171921250961 BOTTLE in 1 CARTON (71921-250-96) / 96 TABLET, COATED in 1 BOTTLE
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
238 interactions on record for lofexidine.
Graded by severity as the source publishes them — 39 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lofexidine · interactions on record
238 records
- 39 severe
- 197 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PapaverinC04AX38severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lofexidine in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2049e581-44d7-4265-a085-0b86489ea661 GET /v1/drugs/2049e581-44d7-4265-a085-0b86489ea661?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": ".18",
"substance": "LOFEXIDINE HYDROCHLORIDE",
"productndc": "71921-250",
"dosage_form": "TABLET, COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA218613",
"marketing_category": "ANDA"
}See everything about lofexidine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.